

**Bringing Critical Race Praxis into the Study of Electrophysiological Substrate of Sudden  
Cardiac Death: The Atherosclerosis Risk in Communities (ARIC) Study**

Kelly Jensen, MD<sup>1</sup>, Stacey J. Howell, MD<sup>1</sup>, Francis Phan, MD<sup>1</sup>, Maedeh Khayyat-Kholghi,  
DO, MS<sup>1</sup>, Linda Wang, BS, MPH<sup>1</sup>, Kazi T. Haq, PhD<sup>1</sup>, John Johnson, BS<sup>1</sup>, Larisa G.  
Tereshchenko, MD, PhD<sup>1,2</sup>.

<sup>1</sup>Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR;

<sup>2</sup>Cardiovascular Division, Department of Medicine, Johns Hopkins School of Medicine,  
Baltimore, MD.

Correspondence: Larisa Tereshchenko, 3181 SW Sam Jackson Park Rd; UHN62; Portland,  
OR, 97239. E-mail:tereshch@ohsu.edu. Phone:503-494-7400; Fax:503-494-8550.

**Brief title: Race and EP substrate of SCD**

Subject Codes: Electrocardiology; Epidemiology, race

ARIC MS # 3292 was approved 10/10/2019

Words: 8104

## Abstract

Race is an established risk factor for sudden cardiac death (SCD). We sought to determine whether the association of electrophysiological (EP) substrate with SCD varies between black and white individuals. Participants from the Atherosclerosis Risk in Communities study with analyzable ECGs (n=14,408; age 54±6 y; 74% white) were included. EP substrate was characterized by traditional 12-lead ECG and vectorcardiographic metrics. Two competing outcomes were adjudicated SCD and non-sudden cardiac death (nonSCD). Interaction of ECG metrics with race was studied in Cox proportional hazards and Fine-Gray competing risk models, adjusted for prevalent cardiovascular disease (CVD), risk factors, and incident non-fatal CVD. At the baseline visit linear regression analysis, adjusted for age, sex, and study center, showed black individuals had larger Spatial Ventricular Gradient magnitude by 0.30 (95% CI 0.25-0.34) mV, SAI QRST by 18.4 (13.7-23.0) mV\*ms, Cornell voltage by 0.30 (95% CI 0.25-0.35) mV than white individuals. Over a median follow-up of 24.4 years, SCD incidence was higher in black (2.86; 95% CI 2.50-3.28 per 1000 person-years) than white individuals (1.37; 95% CI 1.22-1.53 per 1000 person-years). Black individuals with hypertension had the highest rate of SCD: 4.26; 95% CI 3.66-4.96 per 1000 person-years. Race did not modify associations of EP substrate with SCD and nonSCD. EP substrate does not explain racial disparities in SCD rate.

**Key words:** sudden cardiac death, ECG, global electrical heterogeneity, race

## Introduction

Sudden cardiac death (SCD) disproportionately affects black individuals, with a nearly two-fold increased risk of SCD in black as compared to white individuals.<sup>1-3</sup> Socioeconomic disparities and the burden of cardiovascular (CV) risk have been proposed as factors that may underlie the observed racial differences in SCD.<sup>1</sup> However, adjustment for socioeconomic and behavioral measures of health does not fully explain an excess of SCD risk in black individuals.<sup>1, 2, 4</sup> Moreover, the large prospective community-based cohort the Atherosclerosis Risk in Communities (ARIC) study showed that race modifies an association of several major risk factors with SCD. Prevalent coronary heart disease (CHD) and body mass index (BMI) carried greater risk of SCD in white as compared to black individuals.<sup>1</sup> In contrast, hypertension carried significantly larger risk of SCD in black as compared to white individuals.<sup>1</sup> The mechanisms behind these observed interactions remain unclear but pose the question of differences in EP substrate metrics between the two racial groups.

A conventional 12-lead electrocardiogram (ECG) characterizes global electrophysiological (EP) substrate of SCD,<sup>5</sup> which can be assessed by traditional [QRS duration, QTc interval, ECG-left ventricular hypertrophy (LVH)] and novel metrics, such as global electrical heterogeneity (GEH).<sup>6, 7</sup> GEH is measured by spatial QRS-T angle, magnitude and direction (elevation and azimuth) of the spatial ventricular gradient (SVG) vector, and its scalar value sum absolute QRST integral (SAI QRST). The addition of GEH to known CV risk factors improves reclassification of SCD.<sup>8</sup> The SVG vector describes the magnitude and direction of the steepest gradient between the areas of the heart with the longest and the shortest total recovery time.<sup>9-11</sup> The SVG is related to global heterogeneity of action potential duration and morphology<sup>12, 13</sup> through the heart. While racial differences in ECG-LVH diagnostic criteria are recognized<sup>14</sup>, it is

unknown whether there are racial differences in association between EP substrate and risk of SCD.

The self-identified race is a social construct. Recently, the Public Health Critical Race Praxis<sup>15</sup> was developed as a theoretical framework for studies of racial disparities. Our goal was to apply the Public Health Critical Race Praxis<sup>15</sup> approach to the epidemiological study of SCD substrate. We hypothesized that (1) there are racial differences in global ECG measures of EP substrate, and (2) self-identified race modifies the association of EP substrate with SCD.

## **Methods**

The ARIC Study data are available through the National Heart, Lung, and Blood Institute's Biological Specimen and Data Repository Information Coordinating Center (BioLINCC)<sup>16</sup> and the National Center of Biotechnology Information's database of Genotypes and Phenotypes (dbGaP).<sup>17</sup>

### ***Study population***

The Atherosclerosis Risk in Communities (ARIC) study recruited 15,792 participants (age 45-64 y) in 1987-1989. All participants underwent standardized examinations.<sup>18</sup> In this study, we included ARIC cohort participants with recorded resting 12-lead ECG and measured global electrical heterogeneity (GEH)<sup>8</sup>; n=15,777. We excluded participants who self-identified themselves as non-white or non-black race (n=48), or as black at the Washington County, and Minneapolis field centers (n=55), those with missing covariates (n=1,220), outcome (n=1), and non-sinus median beat (n=45). The final sample of participants with normal sinus median beat included 14,408 participants.

### ***Exposures of race and electrocardiographic global electrical heterogeneity***

The race was self-reported. We analyzed resting 12-lead ECGs of the first five study visits. Visit 1 was conducted in 1987-1989, visit 2 in 1990-1992, visit 3 in 1993-1995, visit 4 in 1996-1998, and visit 5 in 2011-2013. Traditional ECG amplitudes and intervals were measured by the 12 SL algorithm as implemented in the Magellan ECG Research Workstation V2 (GE Marquette Electronics, Milwaukee, WI), and Cornell voltage was calculated.

GEH was measured by spatial QRS-T angle, SVG magnitude, azimuth, and elevation, and SAI QRST.<sup>19</sup> Both area and peak SVG vectors and QRS-T angles were measured.<sup>19</sup> We used normal sinus time-coherent median beat with identified isoelectric heart vector origin point.<sup>20</sup> The MATLAB (MathWorks, Natick, MA, USA) open-source software code for GEH measurement and the heart vector origin definition is provided at <https://physionet.org/physiotools/geh> and <https://github.com/Tereshchenkolab/Origin>.

### ***Primary outcome: sudden cardiac death***

Follow-up of ARIC participants<sup>21</sup> and determination of SCD has been described in prior reports.<sup>22</sup> SCD, the primary study outcome, was defined as a sudden pulseless condition in a previously stable participant without a non-cardiac cause of arrest if it occurred outside of the hospital or in the emergency department. It was classified as definite, probable, or possible based on physician-adjudication.

### ***Competing mortality outcome: non-sudden cardiac death***

Competing non-sudden cardiac death (nonSCD) was defined as an SCD exclusion, a composite of fatal CHD, heart failure (HF) death, death in a participant with baseline HF, or incident hospitalized HF. Fatal CHD cases were adjudicated by the ARIC Morbidity and Mortality Classification Committee.<sup>21, 23</sup> Baseline prevalent HF was based on Gothenburg

criteria (stage 3 symptomatic HF with both cardiac and pulmonary symptoms and current medical treatment<sup>24</sup>), or self-reported use of HF medication. Incident HF was defined as presence of HF codes in a death certificate or an International Classification of Diseases (*ICD-9*) discharge code, as previously described.<sup>25</sup> All other deaths were included in the noncardiac death outcome.

### ***Baseline clinical characteristics***

Body mass index (BMI) was categorized as underweight (<18.5 kg/m<sup>2</sup>), normal weight (18.5 to <25.0 kg/m<sup>2</sup>), overweight (25.0 to <30.0 kg/m<sup>2</sup>) or obese (≥30.0 kg/m<sup>2</sup>). Hypertension was defined as blood pressure (BP) of ≥140/90 mm Hg, or self-reported antihypertensive medications at visit 1. Diabetes was defined as nonfasting blood glucose ≥200 mg/dL, fasting blood glucose ≥126 mg/dL, self-reported physician diagnosis of diabetes, or self-reported medications for diabetes or high blood sugar at visit 1. Stages of chronic kidney disease (CKD) were based on estimated glomerular filtration rate (eGFR) calculated using the CKD Epidemiology Collaboration equation (CKD-EPI).<sup>26</sup> Participants were classified into stage 1 CKD (eGFR<sub>CKD-EPI</sub> ≥90 mL/min/1.73 m<sup>2</sup>), stage 2 CKD (eGFR<sub>CKD-EPI</sub> 60 to <90 mL/min/1.73 m<sup>2</sup>), Stage 3 CKD (eGFR<sub>CKD-EPI</sub> 30 to <60 mL/min/1.73 m<sup>2</sup>), stage 4 CKD (eGFR<sub>CKD-EPI</sub> 15 to <30 mL/min/1.73 m<sup>2</sup>), and stage 5 CKD (eGFR<sub>CKD-EPI</sub> <15 mL/min/1.73 m<sup>2</sup>) or established kidney failure. Baseline serum electrolytes concentrations were measured in the central laboratory.

Prevalent stroke was based on a previously reported stroke and transient ischemic attack diagnostic algorithm<sup>27</sup>. Prevalent CHD included a self-reported physician diagnosis of myocardial infarction (MI), baseline ECG evidence of MI by the Minnesota code<sup>28</sup>, or a history of coronary revascularization (either via coronary artery bypass surgery or percutaneous coronary intervention). The use of antiarrhythmic drugs included self-reported and validated by

medications inventory use of class I, II (beta-blockers), III, IV (phenylalkylamines, and benzothiazepines calcium channel blockers), or V (digoxin) antiarrhythmic agents.

### ***Socioeconomic factors***

Socioeconomic status was assessed during a home interview at visit 1. Total combined family income for the past 12 months (in 1987-1989 values) was self-reported in one of the following categories: under \$5,000; \$5,000-\$7,999; \$8,000-\$11,999; \$12,000-\$15,999; \$16,000-\$24,999; \$25,000-\$34,999; \$35,999-\$49,999; over \$50,000, or not reported. Lifetime educational level was defined as the highest grade or year of school completed. The most recent occupation was recorded in one of the following categories: (1) Managerial and Professional Specialty Occupations; (2) Technical, Sales, and Administrative Support Occupations; (3) Service Occupations; (4) Farming, Forestry, and Fishing Occupations; (5) Precision Production, Craft, and Repair Occupations; (6) Operators, Fabricators, and Laborers; (7) Homemakers; (8) Retired; (9) Others.

Baseline physical activity was measured at work, in sport, and during leisure time, using the modified Baecke questionnaire<sup>29</sup>, which defined semicontinuous indices ranging from 1 (low) to 5 (high). Current cigarette smoking and consumption of alcoholic beverages was used as self-reported at visit 1. Self-reported health insurance status was ascertained at visit 1.

### ***Incident non-fatal cardiovascular events***

Incident non-fatal CV events included atrial fibrillation (AF), stroke, CHD, and HF. Incident AF included AF detected on follow-up 12-lead ECG or hospital discharge records (*ICD-9* code 427.3).<sup>30</sup> Physician-adjudicated definite or probable incident strokes were included.<sup>31</sup> Incident CHD was physician-adjudicated and included definite or probable MI or a coronary revascularization procedure.<sup>21, 23</sup> Incident HF was defined above.<sup>25</sup>

## *Statistical analyses*

### *Cross-sectional analyses of visit 1 data*

To investigate differences in global ECG metrics between black and white individuals, we performed cross-sectional linear regression analyses using visit 1 data. Model 1 was adjusted for age, sex, and study center. To determine whether racial differences in GEH could be explained by racial disparities, including differences in socioeconomic, traditional and novel clinical risk factors, Model 2 was additionally adjusted for prevalent cardiovascular (CV) disease (HF, CHD, stroke), known CV risk factors (diabetes, hypertension, current smoking and alcohol intake, work, sport, and leisure physical activity levels, levels of total cholesterol, high density lipoprotein, and triglycerides, BMI), use of antihypertensive and antiarrhythmic medications, serum concentrations of sodium, potassium, calcium, magnesium, phosphorus, and uric acid, total protein and albumin, blood urea nitrogen, CKD stage classified by  $eGFR_{CKD-EPI}$ , traditional ECG characteristics (mean heart rate, QRS duration, Bazett-corrected QT interval, Cornell voltage), and socioeconomic factors (education level, occupation category, income, health insurance).

### *Analysis of circular variables*

Circular variables were analyzed as previously described.<sup>32</sup> SVG azimuth was transformed by doubling its value and then adding  $360^\circ$ .<sup>33</sup>

### *Survival analyses*

We built Cox proportional hazards and Fine-Gray competing risks models. The proportional-hazards assumption was verified using *stcox PH-assumptions* suite of tests implemented in STATA (StataCorp LP, College Station, TX) for all predictors of interest in most models. Exceptions were stated. To standardize comparisons, all continuous ECG variables were



expressed as by their z-score. To adjust for confounders, we constructed two models, performed a statistical test for interaction with race in each model, and constructed race-stratified models for white and black individuals. Relative hazard ratio (RHR) with a 95% confidence interval (CI) of SCD risk for black relative to white individuals was reported, assuming HR for white individuals is a reference.

Model 1 was adjusted for demographic characteristics (age, sex, and study center), prevalent CV disease (HF, CHD, stroke), baseline CV risk factors (diabetes, hypertension, levels of total cholesterol, high density lipoprotein, and triglycerides, BMI, use of antihypertensive and antiarrhythmic medications, serum concentrations of sodium, potassium, calcium, magnesium, phosphorus, and uric acid, total protein and albumin, blood urea nitrogen, CKD stage classified by eGFR<sub>CKD-EPI</sub>), and measured at visit 1 socioeconomic factors (smoking and alcohol intake, work, sport, and leisure physical activity levels, education level, occupation category, income, health insurance). Time-updated model 2 included time-updated ECG predictors (one-by-one), all baseline covariates included in model 1, and time-updated incident nonfatal CV events (AF, HF, CHD, and stroke). Race-stratified associations of continuous ECG variables with SCD were also studied using adjusted (model 1) Cox regression models incorporating cubic splines with 4 knots.

To compare competing risks of SCD and nonSCD, we constructed two Fine and Gray's competing risks models<sup>34</sup> for SCD and nonSCD outcomes, using the same covariates as in Cox models. We calculated the relative sub-hazard ratio (RSHR) with 95% CI of SCD risk for black relative to white individuals, assuming SHR for white participant is a reference.

Based on a recent study demonstrating a significantly stronger association of hypertension with SCD in black as compared to white individuals,<sup>1</sup> we additionally constructed a set of

models that included interaction with both race and hypertension categories. The white hypertension-free subgroup was the reference.

Statistical analyses were performed using STATA MP 16.1 (StataCorp LP, College Station, TX). Considering the many multivariate analyses performed, statistical significance at the 0.05 level should be interpreted cautiously.

## **Results**

### ***Study population***

Black study participants (Table 1) were slightly younger, with a higher prevalence of HF, stroke, and major risk factors (hypertension, diabetes, smoking) than white individuals. White participants had a higher prevalence of CHD, higher level of triglycerides, were less physically active at work, but more physically active at leisure and sport than black participants. There were large disparities between races in access to healthcare, income, education, and occupation.

### ***Differences in ECG metrics between black and white participants***

SVG magnitude, SAI QRST, and Cornell voltage were significantly larger in black than white individuals, even after adjustment for confounders (Table 2 and Figure 1). The spatial QRS-T angle and direction of SVG, as well as QTc were similar in white and black individuals (Supplemental Figure 1).

### ***Association of EP substrate with sudden cardiac death in black and white participants***

Over a median follow-up of 24.4 years, there were 522 SCDs (incidence 1.74; 95% CI 1.59-1.89 per 1000 person-years) and 2,147 nonSCDs (incidence 7.14; 95% CI 6.85-7.45 per 1000 person-years). SCD incidence was two times higher in black (2.86; 95% CI 2.50-3.28 per 1000 person-years) than white participants (1.37; 95% CI 1.22-1.53 per 1000 person-years). Incidence

of nonSCD was higher in black (9.60; 95% CI 8.92-10.33 per 1000 person-years) than white participants (6.33; 95% CI 6.01-6.67 per 1000 person-years).

All traditional ECG metrics, SVG direction, and SAI QRST were associated with a similar risk of SCD in black and white individuals, a finding that was consistent both in Cox regression (Supplemental Table 1A) and competing risk models (Supplemental Table 2A).

Time-updated Cox regression model 2 revealed significant interaction with SVG magnitude. However, competing risk analysis found no effect modification by race of SVG magnitude – SCD association (Figure 2 and Supplemental Table 2). Continuous hazard functions looked similarly for white and black individuals (Supplemental Figure 2), suggesting an absence of meaningful effect modification.

Race did not modify associations of ECG measures with nonSCD (Supplemental Table 2).

### ***Race and hypertension modify an association of spatial QRS-T angle with SCD***

The lowest SCD incidence was observed in hypertension-free white (0.95; 95% CI 0.82-1.11 per 1000 person-years), followed by hypertension-free black (1.31; 95% CI 0.98-1.75 per 1000 person-years), and then by white individuals with hypertension (2.59; 95% CI 2.20-3.04 per 1000 person-years). Black individuals with hypertension had the highest rate of SCD: 4.26; 95% CI 3.66-4.96 per 1000 person-years.

Race significantly modified an association of spatial QRS-T angle with SCD, both in Cox regression (Figure 2 and Supplemental Table 1A) and competing risk models (Figure 2 and Supplemental Table 2A). In white individuals, the spatial QRS-T angle was associated with approximately 20% greater risk of SCD than in black individuals. Adjustment for incident nonfatal CVD in Cox model 2 attenuated the effect modification (Figure 2). In race-stratified Cox regression (Figure 3 and Supplemental Table 1B) and competing risk models 1 and 2

(Figure 4 and Supplemental Table 2B), spatial QRS-T angle was associated with SCD in white, but not black individuals (Figure 5).

Further analysis of the interaction with both race and hypertension showed that spatial QRS-T angle was associated with SCD similarly in white and hypertension-free black individuals (Figure 6 and Supplemental Table 3), but not in black individuals with hypertension. Effect modification by race and hypertension remained significant after adjustment for incident CV events in both Cox regression and competing risk models.

## Discussion

This large, prospective community-based cohort study of more than 14,000 participants showed several important findings. Apart from the QRS-T angle, the association of EP substrate with SCD was similar in black and white individuals. In this study, race did not modify an association of EP substrate with SCD, supporting the recognition of race as a product of social practices, but not an inherent characteristic of individuals. Similar strength of the association of global ECG metrics with SCD in black and white individuals implies that EP substrate does not explain racial disparities in SCD rate.

Furthermore, we observed that black individuals with hypertension experienced 4.5-fold higher SCD incidence than hypertension-free white individuals. Black race in the presence of hypertension is associated with very high SCD risk regardless of QRS-T angle, which explains the weaker association of QRS-T angle with SCD in black than white individuals. However, relative risk of SCD carried by QRS-T angle did not differ in hypertension-free black and white individuals with or without hypertension. We also observed that black individuals had larger amplitude-based ECG metrics (SAI QRST, SVG magnitude, Cornell voltage) as compared to

white individuals. The difference of approximately 0.3 mV was robustly observed even after accounting for socioeconomic status and other confounders. This finding is consistent with previous studies<sup>35, 36</sup> and supports use of race-specific thresholds for abnormal SAI QRST,<sup>8</sup> SVG magnitude,<sup>8</sup> and ECG-LVH.<sup>14, 37</sup>

### ***Race does not modify an association of EP substrate with SCD***

Our study found that all traditional ECG metrics (QTc duration, QRS duration, and Cornell voltage), SVG direction, and SAI QRST were associated with a similar risk of SCD among black and white individuals. There is little existing literature studying the association of ECG metrics and risk of SCD by race, and this study provides new insight into racial differences and similarities. In a prior study on sex differences,<sup>32</sup> we found that Cornell voltage, SVG magnitude, and SAI QRST are associated with a 16-24% greater risk of SCD in women as compared to men. Sex is biologically determined and therefore may cause differences in EP substrate in contrast to race, which is a complex social construct.

There has been growing recognition of the Critical Race Theory<sup>38</sup>, which aims to better account for the effects of institutionalized racism on health. Critical Race Theory aims to acknowledge inequities in the biomedical field and bring to light both discrimination and health consequences that result from discrimination and inequalities in access to healthcare. Race is a product of social processes of power. The Critical Race Theory defines race not as an inherent characteristic of a person, but as a product of social practices.<sup>38</sup> Results of our study support the Critical Race Theory postulate. Many previous studies recognized race as an independent and strong risk factor of SCD even after adjusting for socioeconomic factors but attributed it - at least partially – to underlying biological differences between black and white individuals.<sup>1, 2, 4</sup> In contrast, our comprehensive study of EP substrate did not find meaningful effect modification by

race. Results of our study call attention to structural racism as an important determinant of the increased SCD rate in black as compared to white individuals.<sup>39</sup>

A number of studies investigated the effects of racism on physical health. These studies showed that self-reported daily discrimination and stress was associated with increased waist circumference, increased waist to hip ratio, and higher fasting glucose level.<sup>40-42</sup> Not only does daily stress increase potential risk factors for SCD, but long-term negative emotions also increase vulnerability to life-threatening arrhythmias<sup>43</sup> and can potentially contribute to racial disparities in SCD.

When thinking about race and potential biological differences determining health, it is important to consider that race is not equivalent to genetic ancestry, but as mentioned above is a social construct. In our study, participants self-identified as black or white, but no ancestry information was analyzed. Ancestry analyses of the self-reported racial and ethnic identity in the US have shown that self-identified black individuals carry up to 24% of European ancestry, and about 1 in 10 self-identified white individuals in the US South have at least 1% of African ancestry.<sup>44</sup> Association of genetic ancestry with EP substrate of SCD<sup>4</sup> deserves separate investigation.

Clinical implications for the finding of no meaningful effect modification by race suggests that there is no need for race-specific risk stratification of SCD. Instead, race should be included in the SCD risk models as a potent risk marker.<sup>8</sup>

### ***Race-specific thresholds of ECG voltage measurements***

Racial differences in ECG voltage and ECG-LVH definition have been previously reported.<sup>35-37</sup> This study showed consistent results: voltage-based ECG metrics (SVG magnitude, SAI QRST, Cornell voltage) were larger in black than white individuals, by 0.2-0.3 mV.

Comprehensive adjustment for cardiovascular risk factors in this study did not affect the racial differences in SVG magnitude, SAI QRST, and Cornell voltage. Similarly, the Dallas Heart Study reported<sup>45</sup> that after adjustment for cardiovascular risk factors and body composition, both black race and African ancestry were associated with approximately 0.25 mV larger ECG voltage. Of note, in our study, racial differences in SVG magnitude, SAI QRST, and Cornell voltage did not translate into different strengths of their associations with SCD.

A recent genome-wide association study of GEH revealed 10 GEH-associated loci.<sup>46</sup> Four loci (11p11.2 cluster, near *ACTB*, *LUZP1-KDM1A*, and *IGF1R*) were associated with increase in both SAI QRST and SVG magnitude. *IGF1R* is a key signaling step in *physiologic* cardiomyocyte hypertrophy<sup>47</sup>, which can potentially explain why increased SAI QRST, SVG magnitude, and Cornell voltage in black individuals did not translate into stronger association of these ECG measures with SCD. SAI QRST – associated locus near *LUZP1-KDM1A* has higher effect allele frequency<sup>46</sup> in African ancestry (0.92) as compared to European ancestry (0.59), which can potentially contribute to larger SAI QRST in a black population. Further studies are needed to test these hypotheses.

### ***Strengths and Limitations***

The strengths of our study included the sizeable community-dwelling cohort, the extended follow-up, and the rigorous adjudication of SCD. We were also able to adjust for time-varying ECG measurements and incident nonfatal cardiovascular events and conduct competing risk analyses. However, our study has limitations, as previously acknowledged.<sup>8</sup> While efforts were made to differentiate SCD from nonSCD, it is possible that some SCD events were secondary to sudden non-cardiac catastrophe as opposed to ventricular arrhythmias. However, these events likely compromise a small fraction of SCD events and therefore should not significantly affect

study results. This study did not include resuscitated out-of-hospital cardiac arrest due to difficulty accurately differentiating its cause. Another important consideration is the inclusion of only black and white individuals, which limits generalizability to the multiethnic populations. Further studies in other races and ethnicities are needed to validate our findings.

***Acknowledgments:***

The authors thank the staff and participants of the ARIC study for their important contributions. We would like to acknowledge the SCD mortality classification committee members: Nona Sotoodehnia (lead), Selcuk Adabag, Sunil Agarwal, Lin Chen, Rajat Deo, Leonard Ilkhanoff, Liviu Klein, Saman Nazarian, Ashleigh Owen, Kris Patton, and Larisa Tereshchenko.

***Funding Sources:***

The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, HHSN268201700005I). This work was supported by HL118277 (LGT), and OHSU President Bridge funding (LGT).

***Disclosures***

None.



## References

1. Zhao D, Post WS, Blasco-Colmenares E, Cheng A, Zhang Y, Deo R, Pastor-Barriuso R, Michos ED, Sotoodehnia N and Guallar E. Racial Differences in Sudden Cardiac Death. *Circulation*. 2019;139:1688-1697.
2. Deo R, Safford MM, Khodneva YA, Jannat-Khah DP, Brown TM, Judd SE, McClellan WM, Rhodes JD, Shlipak MG, Soliman EZ and Albert CM. Differences in Risk of Sudden Cardiac Death Between Blacks and Whites. *J Am Coll Cardiol*. 2018;72:2431-2439.
3. Tseng ZH, Olgin JE, Vittinghoff E, Ursell PC, Kim AS, Sporer K, Yeh C, Colburn B, Clark NM, Khan R, Hart AP and Moffatt E. Prospective Countywide Surveillance and Autopsy Characterization of Sudden Cardiac Death: POST SCD Study. *Circulation*. 2018;137:2689-2700.
4. Fender EA, Henrikson CA and Tereshchenko L. Racial differences in sudden cardiac death. *J Electrocardiol*. 2014;47:815-8.
5. Tereshchenko LG. Electrocardiogram as a screening tool in the general population: A strategic review. *Journal of Electrocardiology*. 2013;46:553-556.
6. Tereshchenko LG. Global Electrical Heterogeneity: Mechanisms and Clinical Significance. *2018 Computing in Cardiology Conference (CinC)*. 2018;45:e165
7. Waks JW and Tereshchenko LG. Global electrical heterogeneity: A review of the spatial ventricular gradient. *J Electrocardiol*. 2016;49:824-830.
8. Waks JW, Sitlani CM, Soliman EZ, Kabir M, Ghafoori E, Biggs ML, Henrikson CA, Sotoodehnia N, Biering-Sorensen T, Agarwal SK, Siscovick DS, Post WS, Solomon SD, Buxton AE, Josephson ME and Tereshchenko LG. Global Electric Heterogeneity Risk Score for Prediction of Sudden Cardiac Death in the General Population: The Atherosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. *Circulation*. 2016;133:2222-34.

9. Burger HC. A theoretical elucidation of the notion ventricular gradient. *American Heart Journal*. 1957;53:240-246.
10. Wilson FN, Macleod AG, Barker PS and Johnston FD. The determination and the significance of the areas of the ventricular deflections of the electrocardiogram. *American Heart Journal*. 1934;10:46-61.
11. Wilson FN, MacLeod, A.G., Barker, P.S. The T deflection of the electrocardiogram. *Trans Assoc Am Physicians*. 1931;46:29-38.
12. Plonsey R. A contemporary view of the ventricular gradient of Wilson. *J Electrocardiol*. 1979;12:337-341.
13. Geselowitz DB. The ventricular gradient revisited: relation to the area under the action potential. *IEEE Trans BiomedEng*. 1983;30:76-77.
14. Okin PM, Wright JT, Nieminen MS, Jern S, Taylor AL, Phillips R, Papademetriou V, Clark LT, Ofili EO, Randall OS, Oikarinen L, Viitasalo M, Toivonen L, Julius S, Dahlof B and Devereux RB. Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. *Am J Hypertens*. 2002;15:663-671.
15. Ford CL and Airhihenbuwa CO. Commentary: Just What is Critical Race Theory and What's it Doing in a Progressive Field like Public Health? *Ethnicity & disease*. 2018;28:223-230.
16. Coady SA, Mensah GA, Wagner EL, Goldfarb ME, Hitchcock DM and Giffen CA. Use of the National Heart, Lung, and Blood Institute Data Repository. *N Engl J Med*. 2017;376:1849-1858.
17. Tryka KA, Hao L, Sturcke A, Jin Y, Wang ZY, Ziyabari L, Lee M, Popova N, Sharopova N, Kimura M and Feolo M. NCBI's Database of Genotypes and Phenotypes: dbGaP. *Nucleic Acids Res*. 2014;42:D975-9.

18. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. *Am J Epidemiol.* 1989;129:687-702.
19. Thomas JA, E AP-A, Junell A, Newton K, Hamilton C, Li-Pershing Y, German D, Bender A and Tereshchenko LG. Vectorcardiogram in athletes: The Sun Valley Ski Study. *Ann Noninvasive Electrocardiol.* 2019;24:e12614.
20. Perez-Alday EA, Li-Pershing Y, Bender A, Hamilton C, Thomas JA, Johnson K, Lee TL, Gonzales R, Li A, Newton K and Tereshchenko LG. Importance of the heart vector origin point definition for an ECG analysis: The Atherosclerosis Risk in Communities (ARIC) study. *Comput Biol Med.* 2019;104:127-138.
21. White AD, Folsom AR, Chambless LE, Sharret AR, Yang K, Conwill D, Higgins M, Williams OD and Tyroler HA. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. *Journal of clinical epidemiology.* 1996;49:223-33.
22. O'Neal WT, Singleton MJ, Roberts JD, Tereshchenko LG, Sotoodehnia N, Chen LY, Marcus GM and Soliman EZ. Association Between QT-Interval Components and Sudden Cardiac Death: The ARIC Study (Atherosclerosis Risk in Communities). *Circ Arrhythm Electrophysiol.* 2017;10.
23. Luepker RV, Apple FS, Christenson RH, Crow RS, Fortmann SP, Goff D, Goldberg RJ, Hand MM, Jaffe AS, Julian DG, Levy D, Manolio T, Mendis S, Mensah G, Pajak A, Prineas RJ, Reddy KS, Roger VL, Rosamond WD, Shahar E, Sharrett AR, Sorlie P and Tunstall-Pedoe H. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of

- Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. *Circulation*. 2003;108:2543-2549.
24. Eriksson H, Caidahl K, Larsson B, Ohlson LO, Welin L, Wilhelmsen L and Svardsudd K. Cardiac and pulmonary causes of dyspnoea--validation of a scoring test for clinical-epidemiological use: the Study of Men Born in 1913. *Eur Heart J*. 1987;8:1007-14.
25. Loehr LR, Rosamond WD, Chang PP, Folsom AR and Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). *Am J Cardiol*. 2008;101:1016-1022.
26. Matsushita K, Selvin E, Bash LD, Astor BC and Coresh J. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study. *Am J Kidney Dis*. 2010;55:648-659.
27. Toole JF, Chambless LE, Heiss G, Tyroler HA and Paton CC. Prevalence of stroke and transient ischemic attacks in the atherosclerosis risk in communities (ARIC) study. *Annals of Epidemiology*. 1993;3:500-503.
28. Blackburn H, Keys A, Simonson E, Rautaharju P and Punsar S. The electrocardiogram in population studies. A classification system. *Circulation*. 1960;21:1160-1175.
29. Richardson MT, Ainsworth BE, Wu HC, Jacobs DR, Jr. and Leon AS. Ability of the Atherosclerosis Risk in Communities (ARIC)/Baecke Questionnaire to assess leisure-time physical activity. *Int J Epidemiol*. 1995;24:685-93.
30. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ and Folsom AR. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. *Am Heart J*. 2009;158:111-7.

31. Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, Copper LS and Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. *Stroke*. 1999;30:736-743.
32. Howell SJ, German D, Bender A, Phan F, Mukundan SV, Perez-Alday EA, Rogovoy NM, Haq K, Yang K, Wirth A, Jensen K and Tereshchenko LG. Does Sex Modify an Association of Electrophysiological Substrate with Sudden Cardiac Death? The Atherosclerosis Risk in Communities (ARIC) Study. *bioRxiv*. 2019:674689.
33. Cox NJ. Speaking Stata: In Praise of Trigonometric Predictors. *The Stata Journal*. 2006;6:561-579.
34. Fine JP and Gray RJ. A proportional hazards model for the subdistribution of a competing risk. *Journal of the American Statistical Association*. 1999;94:496-509.
35. Rautaharju PM, Zhou SH and Calhoun HP. Ethnic differences in ECG amplitudes in North American white, black, and Hispanic men and women. Effect of obesity and age. *J Electrocardiol*. 1994;27 Suppl:20-31.
36. Vitelli LL, Crow RS, Shahar E, Hutchinson RG, Rautaharju PM and Folsom AR. Electrocardiographic findings in a healthy biracial population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. *Am J Cardiol*. 1998;81:453-459.
37. Rautaharju PM, Park LP, Gottdiener JS, Siscovick D, Boineau R, Smith V and Powe NR. Race- and sex-specific ECG models for left ventricular mass in older populations. Factors influencing overestimation of left ventricular hypertrophy prevalence by ECG criteria in African-Americans. *J Electrocardiol*. 2000;33:205-218.
38. Bridges KM, Keel T and Obasogie OK. Introduction: Critical Race Theory and the Health Sciences. *Am J Law Med*. 2017;43:179-182.

39. Galea S, Blaney S, Nandi A, Silverman R, Vlahov D, Foltin G, Kusick M, Tunik M and Richmond N. Explaining racial disparities in incidence of and survival from out-of-hospital cardiac arrest. *Am J Epidemiol.* 2007;166:534-43.
40. Hunte HE. Association between perceived interpersonal everyday discrimination and waist circumference over a 9-year period in the Midlife Development in the United States cohort study. *Am J Epidemiol.* 2011;173:1232-9.
41. Vines AI, Baird DD, Stevens J, Hertz-Picciotto I, Light KC and McNeilly M. Associations of abdominal fat with perceived racism and passive emotional responses to racism in African American women. *Am J Public Health.* 2007;97:526-30.
42. Butler C, Tull ES, Chambers EC and Taylor J. Internalized racism, body fat distribution, and abnormal fasting glucose among African-Caribbean women in Dominica, West Indies. *J Natl Med Assoc.* 2002;94:143-8.
43. Lampert R. Mental Stress and Ventricular Arrhythmias. *Curr Cardiol Rep.* 2016;18:118.
44. Bryc K, Durand EY, Macpherson JM, Reich D and Mountain JL. The genetic ancestry of African Americans, Latinos, and European Americans across the United States. *American journal of human genetics.* 2015;96:37-53.
45. Alame AJ, Garg S, Kozlitina J, Ayers C, Peshock RM, Matulevicius SA and Drazner MH. Association of African Ancestry With Electrocardiographic Voltage and Concentric Left Ventricular Hypertrophy: The Dallas Heart Study. *JAMA Cardiol.* 2018;3:1167-1173.
46. Tereshchenko LG, Sotoodehnia N, Sitlani CM, Ashar FN, Kabir M, Biggs ML, Morley MP, Waks JW, Soliman EZ, Buxton AE, Biering-Sorensen T, Solomon SD, Post WS, Cappola TP, Siscovick DS and Arking DE. Genome-Wide Associations of Global Electrical

Heterogeneity ECG Phenotype: The ARIC (Atherosclerosis Risk in Communities) Study and CHS (Cardiovascular Health Study). *J Am Heart Assoc.* 2018;7:e008160.

47. Weeks KL, Bernardo BC, Ooi JYY, Patterson NL and McMullen JR. The IGF1-PI3K-Akt Signaling Pathway in Mediating Exercise-Induced Cardiac Hypertrophy and Protection. *Adv Exp Med Biol.* 2017;1000:187-210.

**Table 1. Comparison of baseline clinical and ECG characteristics in black and white participants**

Characteristics	Black (n=3,739)	White (n=10,669)
Age(SD), y	53.5(5.8)	54.4(5.7)
Female, n(%)	2,309(61.8)	5,622(52.7)
Heart Failure, n(%)	257(6.9)	407(3.8)
Coronary heart disease, n(%)	148(4.0)	534(5.0)
Stroke, n(%)	106(2.8)	138(1.29)
Body mass index(SD), kg/m <sup>2</sup>	29.6(6.2)	27.0(4.9)
Diabetes, n(%)	733(19.6)	965(9.0)
Hypertension, n(%)	2,077(55.6)	2,886(27.1)
Antihypertensive drugs, n(%)	1,644(44.0)	2,731(25.6)
Current tobacco smoker, n(%)	1,126(30.1)	2,643(24.8)
Current alcohol drinker, n(%)	1,189(31.8)	6,894(64.6)
Leisure physical activity score(SD)	2.1(0.6)	2.5(0.5)
Sport physical activity score(SD)	2.2(0.7)	2.5(0.8)
Work physical activity score(SD)	2.3(1.0)	2.1(0.9)
Family income <\$25,000, n(%)	2,406(64.4)	2,779(26.0)
Education less than high school, n(%)	1,538(41.1)	1,813(17.0)
Health Insurance, n(%)	2,883(77.1)	10,163(95.3)
Total cholesterol(SD), mmol/L	5.6(1.2)	5.6(1.1)
HDL cholesterol(SD), mg/dL	55.2(17.7)	50.4(16.7)
Triglycerides(SD), mmol/L	1.3(0.9)	1.6(1.0)
Sodium(SD), mmol/L	141.2(2.6)	140.9(2.4)
Potassium(SD), mmol/L	4.2(0.5)	4.5(0.5)
Calcium(SD), mg/dL	9.84(0.5)	9.77(
Magnesium(SD), mEq/L	1.6(0.2)	1.7(0.1)
Phosphorus(SD), mg/dL	3.47(0.54)	3.42(0.48)
Total protein(SD), mg/dL	7.55(0.47)	7.18(0.40)
Albumin(SD), mg/dL	3.8(0.3)	3.9(0.3)
Blood urea nitrogen(SD), mg/dL	14.6(5.6)	15.5(3.8)
Chronic kidney disease stage≤1, n(%)	2,901(77.6)	7,039(66.0)
Uric acid(SD), mg/dL	6.3(1.7)	6.0(1.5)
Use of antiarrhythmic drugs, n(%)	548(14.7)	1,464(13.7)
Heart rate(SD), bpm	66.5(11.0)	66.2(9.9)
QRS duration(SD), ms	91.4(12.6)	92.5(12.2)
QTc(SD), ms	418(21)	416(18)



Cornell voltage(SD), mV	1.5(0.6)	1.2(0.5)
Peak QRS-T angle(circular SD), °	47.3(36.3)	40.6(30.2)
Area QRS-T angle(circular SD), °	60.8(29.4)	60.4(27.6)
Peak SVG elevation(circular SD), °	66.4(14.2)	62.4(15.5)
Area SVG elevation(circular SD), °	71.5(15.9)	66.0(17.5)
Peak SVG azimuth(circular SD), °	6.7(19.5)	1.2(21.1)
Area SVG azimuth(circular SD), °	25.2(21.5)	24.6(21.5)
SAI QRST, mV*ms	157(60)	139(46)
Peak SVG magnitude(SD), mV	1.8(0.5)	1.5(0.4)
SVG magnitude, mV	2.0(0.5)	1.6(0.4)

---

HDL=High-density lipoprotein; SD=standard deviation

**Table 2. Difference in GEH variables in black as compared to white participants**

GEH characteristic	Model 1	Model 2
	Difference (95%CI)	Difference (95%CI)
Peak QRS-T angle, °	+11(8.6-15.0)	+5.2(2.2-8.3)
Area QRS-T angle, °	+1.4(-1.2 to 4.1)	-2.7(-5.2 to -0.3)
Peak SVG elevation, °	+4.6(3.1-6.0)	+0.8(-0.5 to 2.2)
Area SVG elevation, °	+6.1(4.5-7.8)	+2.3(0.6-3.9)
Peak SVG azimuth, °	+11.0(5.8-15.6)	+0.3(-4.5 to 5.0)
Area SVG azimuth, °	+1.8(-3.1 to 6.7)	-11.3(-15.9 to -6.6)
SAI QRST, mV*ms	+18.4(13.7-23.0)	+14.0(9.8-18.0)
Peak SVG magnitude, mV	+0.26(0.21-0.30)	+0.22(0.1800.26)
SVG magnitude, mV	+0.30(0.25-0.34)	+0.28(0.23-0.33)
Cornell voltage, mV	+0.30(0.25-0.35)	+0.22(0.18-0.27)
QRS duration, ms	-0.4(-1.6 to 0.7)	-3.3(-4.4 to -2.2)
QTc, ms	+2.4(0.5-4.2)	-0.6(-2.3 to 1.1)
Heart rate, bpm	-0.8(-1.8 to 0.2)	-3.2(-4.2 to -2.3)

## Figure legends

**Figure 1.** Estimated adjusted marginal (least-squares) means and 95% Confidence Intervals (CI) of (A) peak SVG magnitude, (B) area SVG magnitude, (C) SAI QRST, and (D) Cornell voltage for white and black participants. Model 1 was adjusted for age, sex, and study center. Model 2 was additionally adjusted for HF, CHD, stroke, diabetes, hypertension, current smoking and alcohol intake, work, sport, and leisure physical activity levels, levels of total cholesterol, high density lipoprotein, and triglycerides, BMI, use of antihypertensive and antiarrhythmic medications, serum concentrations of sodium, potassium, calcium, magnesium, phosphorus, and uric acid, total protein and albumin, blood urea nitrogen, and CKD stage classified by  $eGFR_{CKD-EPI}$ , heart rate, QRS duration, Bazett-corrected QT interval, Cornell voltage, education level, occupation category, income, and health insurance.

**Figure 2.** Adjusted Cox proportional relative hazard ratio (RHR) and competing SCD risk relative sub-hazard risk ratio (RSHR) with 95% confidence interval (CI) for black as compared to white participants, with HR/SHR for white participants equal 1.0. Models 1 (green diamond) and models 2 (orange triangle) for the QRS-T angle and SVG magnitude are shown. Black lines correspond to 95% CI bounds.

**Figure 3.** Sex-stratified adjusted (models 1 and 2) Cox proportional hazard ratio (HR) and 95% CI of SCD for QRS-T angle and SVG magnitude in white (hollow rectangle) and black (black oval) individuals. Black lines correspond to 95% CI bounds.

**Figure 4.** Adjusted (models 1 and 2) competing risk sub-hazard ratio (SHR) and 95% CI of SCD for QRS-T angle and SVG magnitude in white (hollow rectangle) and black (black oval) individuals. Black lines correspond to 95% CI bounds.

**Figure 5.** Adjusted (model 1) risk of SCD associated with area and peak QRS-T angle in black and white participants. Restricted cubic spline with 95% CI shows a change in the hazard ratio (Y-axis) in response to QRS-T angle change (X-axis). 50th percentile of QRS-T angle is selected as reference. Knots of peak QRS-T angle in white participants are at 10 – 28 – 44 -118 degrees, and in black participants are at 11 – 31 – 53 – 149 degrees. Knots of area QRS-T angle in white participants are at 22 – 48 – 69 – 112 degrees, and in black participants are at 21 – 48 – 69 - 118 degrees.

**Figure 6.** Adjusted (model 1) risk of SCD associated with area and peak QRS-T angle in black participants with and without hypertension. Restricted cubic spline with 95% CI shows a change in hazard ratio (Y-axis) in response to QRS-T angle change (X-axis). 50th percentile of QRS-T angle is selected as reference. Knots of peak QRS-T angle are at 10 – 29 – 45 - 120 degrees. Knots of area QRS-T angle in black participants with hypertension are at 21 – 50– 72 - 130 degrees, and in hypertension – free black participants are at 20 – 46 – 66 - 103 degrees.

Figure 1:




Figure 2:





Figure 3:



**Figure 4:**






Figure 5:





Figure 6:



**Supplemental Table 1A: Race interaction in association of global ECG measures with SCD in**

**Cox models**

Predictor, per 1 SD		All (n=14,408; 522 SCDs)			
		HR(95%CI)	P-value	RHR for black vs. white pts (95%CI)	P <sub>interaction</sub>
Model 1	Peak QRS-T angle	<b>1.34(1.22-1.47)</b>	<b>&lt;0.0001</b>	<b>0.86(0.75-0.98)</b>	<b>0.026</b>
	Area QRS-T angle	<b>1.35(1.21-1.51)</b>	<b>&lt;0.0001</b>	<b>0.78(0.67-0.90)</b>	<b>0.001</b>
	Peak SVG elevation	<b>1.13(1.01-1.26)</b>	<b>0.027</b>	0.92(0.78-1.09)	0.348
	Area SVG elevation	<b>1.16(1.06-1.28)</b>	<b>0.002</b>	0.88(0.75-1.04)	0.136
	Peak SVG azimuth	<b>1.11(1.01-1.21)</b>	<b>0.026</b>	1.01(0.88-1.15)	0.940
	Area SVG azimuth	0.99(0.90-1.09)	0.878	1.07(0.92-1.25)	0.389
	Peak SVG magnitude	0.89(0.79-1.01)	0.083	1.17(0.98-1.40)	0.083
	Area SVG magnitude	0.98(0.86-1.11)	0.753	1.09(0.92-1.29)	0.314
	SAI QRST	<b>1.21(1.08-1.35)</b>	<b>0.001</b>	0.89(0.79-1.01)	0.078
	Heart rate	1.11(0.99-1.24)	0.081	1.01(0.86-1.19)	0.907
	Bazett's QTc	<b>1.12(1.01-1.24)</b>	<b>0.032</b>	1.01(0.89-1.14)	0.924
	QRS duration	1.07(0.98-1.18)	0.128	0.93(0.81-1.07)	0.304
	Cornell voltage	1.10(0.98-1.24)	0.104	1.01(0.87-1.18)	0.893
	Model 2	Peak QRS-T angle	<b>1.24(1.12-1.36)</b>	<b>&lt;0.0001</b>	0.89(0.77-1.03)
Area QRS-T angle		<b>1.27(1.15-1.40)</b>	<b>&lt;0.0001</b>	<b>0.83(0.72-0.97)</b>	<b>0.020</b>
Peak SVG elevation		<b>1.14(1.03-1.27)</b>	<b>0.011</b>	0.96(0.81-1.15)	0.675
Area SVG elevation		<b>1.12(1.01-1.23)</b>	<b>0.035</b>	0.97(0.81-1.16)	0.726
Peak SVG azimuth		<b>1.12(1.02-1.22)#</b>	<b>0.015</b>	1.04(0.90-1.21)	0.602
Area SVG azimuth		1.04(0.95-1.15)	0.387	1.11(0.93-1.32)	0.246
Peak SVG magnitude		0.98(0.86-1.11)	0.720	<b>1.19(1.001-1.41)</b>	<b>0.048</b>
Area SVG magnitude		0.93(0.82-1.07)	0.310	<b>1.24(1.04-1.66)</b>	<b>0.018</b>
SAI QRST		<b>1.10(1.02-1.19)</b>	<b>0.013</b>	1.01(0.91-1.12)	0.865
Heart rate		1.11(0.99-1.24)	0.078	1.04(0.89-1.23)	0.600
Bazett's QTc		<b>1.16(1.06-1.27)#</b>	<b>0.002</b>	1.01(0.88-1.15)	0.916
QRS duration		<b>1.18(1.09-1.29)</b>	<b>&lt;0.0001</b>	0.96(0.84-1.10)	0.575
Cornell voltage		1.06(0.97-1.16)	0.187	1.09(0.97-1.23)	0.135

#Proportionality hazards assumption not met; SVG=spatial ventricular gradient; RHR=relative hazard ratio.

**Supplemental Table 1B: Association of GEH with SCD in Cox models for white and black participants**

	Predictor, per 1 SD	White (n=10,669; 309 SCDs)		Black (n=3,739; 213 SCDs)	
		HR(95%CI)	P-value	HR(95%CI)	P-value
Model 1	Peak QRS-T angle	<b>1.34(1.21-1.48)</b>	<b>&lt;0.0001</b>	<b>1.15(1.02-1.30)</b>	<b>0.018</b>
	Area QRS-T angle	<b>1.38(1.22-1.55)</b>	<b>&lt;0.0001</b>	1.05(0.91-1.22)	0.467
	Peak SVG elevation	<b>1.13(1.01-1.27)</b>	<b>0.032</b>	1.05(0.90-1.23)	0.523
	Area SVG elevation	<b>1.17(1.06-1.30)</b>	<b>0.002</b>	1.05(0.90-1.21)	0.555
	Peak SVG azimuth	<b>1.10(1.003-1.21)</b>	<b>0.044</b>	1.10(0.97-1.26)	0.129
	Area SVG azimuth	0.99(0.90-1.10)	0.901	1.05(0.91-1.22)	0.471
	Peak SVG magnitude	0.92(0.81-1.04)	0.198	1.01(0.88-1.15)	0.915
	Area SVG magnitude	1.01(0.88-1.15)	0.935	1.03(0.90-1.18)	0.625
	SAI QRST	<b>1.23(1.08-1.39)</b>	<b>0.001</b>	1.07(0.95-1.21)	0.270
	Heart rate	1.11(0.98-1.26)	0.090	<b>1.16(1.02-1.32)</b>	<b>0.029</b>
	Bazett's QTc	<b>1.18(1.03-1.29)</b>	<b>0.010</b>	<b>1.11(1.002-1.23)</b>	<b>0.046</b>
	QRS duration	1.06(0.95-1.18)	0.272	1.04(0.92-1.18)	0.510
	Cornell voltage	1.07(0.95-1.22)	0.256	<b>1.15(1.02-1.30)</b>	<b>0.018</b>
Model 2	Peak QRS-T angle	<b>1.23(1.12-1.36)</b>	<b>&lt;0.0001</b>	1.09(0.96-1.24)	0.171
	Area QRS-T angle	<b>1.27(1.15-1.41)</b>	<b>&lt;0.0001</b>	1.06(0.93-1.22)	0.373
	Peak SVG elevation	<b>1.16(1.04-1.29)</b>	<b>0.006</b>	1.12(0.96-1.30)	0.147
	Area SVG elevation	<b>1.13(1.02-1.25)</b>	<b>0.021</b>	1.09(0.94-1.28)	0.251
	Peak SVG azimuth	<b>1.11(1.01-1.21)</b>	<b>0.022</b>	<b>1.16(1.02-1.32)</b>	<b>0.023</b>
	Area SVG azimuth	<b>1.05(0.95-1.16)</b>	<b>0.359</b>	1.15(0.99-1.34) #	0.074
	Peak SVG magnitude	0.96(0.84-1.10)	0.595	1.08(0.95-1.23)	0.236
	Area SVG magnitude	1.00(0.88-1.14)	0.964	1.09(0.96-1.24)	0.183
	SAI QRST	<b>1.13(1.04-1.22)</b>	<b>0.004</b>	<b>1.11(1.01-1.21)</b>	<b>0.023</b>
	Heart rate	1.09(0.97-1.23)	0.134	<b>1.20(1.06-1.36)</b>	<b>0.005</b>
	Bazett's QTc	<b>1.19(1.09-1.30)</b>	<b>&lt;0.0001</b>	<b>1.16(1.05-1.29)</b>	<b>0.004</b>
	QRS duration	<b>1.18(1.08-1.29)</b>	<b>&lt;0.0001</b>	<b>1.15(1.03-1.30)</b>	<b>0.015</b>
	Cornell voltage	1.08(0.99-1.19)	0.082	<b>1.16(1.06-1.27)</b>	<b>0.001</b>

#Proportionality hazards assumption not met; SVG=spatial ventricular gradient.

**Supplemental Table 2A. Race interaction in association of GEH with SCD and nonSCD in competing risk models**

Predictor, per 1 SD	SCD (n=14,408; 522 SCDs)				nonSCD (n=14,408; 2,147 nonSCDs)				
	SHR(95% CI)	P-value	RSHR for black vs.white (95% CI)	P <sub>interaction</sub>	SHR(95% CI)	P-value	RSHR for black vs.white (95% CI)	P <sub>interaction</sub>	
Model 1	Peak QRS-T angle	<b>1.28(1.16-1.40)</b>	<b>&lt;0.0001</b>	<b>0.85(0.75-0.98)</b>	<b>0.022</b>	<b>1.11(1.05-1.17)</b>	<b>&lt;0.0001</b>	1.01(0.93-1.09)	0.979
	Area QRS-T angle	<b>1.25(1.13-1.39)</b>	<b>&lt;0.0001</b>	<b>0.79(0.69-0.92)</b>	<b>0.002</b>	<b>1.15(1.08-1.22)</b>	<b>&lt;0.0001</b>	1.00(0.91-1.09)	0.914
	Peak SVG elevation	1.11(0.99-1.25)	0.075	0.96(0.80-1.14)	0.630	1.00(0.95-1.06)	0.869	0.930(0.84-1.03)	0.148
	Area SVG elevation	<b>1.14(1.03-1.25)</b>	<b>0.010</b>	0.94(0.80-1.11)	0.471	1.00(0.94-1.05)	0.904	0.96(0.87-1.05)	0.398
	Peak SVG azimuth	1.09(0.99-1.19)	0.071	1.02(0.89-1.18)	0.755	1.04(0.99-1.09)	0.168	0.99(0.91-1.09)	0.890
	Area SVG azimuth	0.98(0.88-1.08)	0.640	1.07(0.91-1.64)	0.426	<b>1.07(1.01-1.13)</b>	<b>0.017</b>	0.99(0.90-1.09)	0.837
	Peak SVG magnitude	0.90(0.79-1.02)	0.096	1.10(0.93-1.31)	0.263	0.96(0.90-1.02)	0.170	1.10(0.99-1.21)	0.073
	Area SVG magnitude	0.98(0.87-1.11)	0.727	1.02(0.87-1.21)	0.792	0.98(0.92-1.05)	0.608	1.08(0.98-1.19)	0.114
	SAI QRST	<b>1.13(1.02-1.26)</b>	<b>0.019</b>	0.88(0.77-1.01)	0.076	1.05(0.98-1.13)	0.192	1.01(0.93-1.10)	0.751
	Heart rate.	1.03(0.92-1.16)	0.576	0.99(0.84-1.17)	0.918	<b>1.13(1.07-1.20)</b>	<b>&lt;0.0001</b>	1.07(0.98-1.17)	0.128
	Bazett's QTc	1.09(0.98-1.21)	0.124	1.02(0.90-1.17)	0.737	1.05(0.996-1.11)	0.071	1.02(0.94-1.09)	0.673
	QRS duration	1.06(0.95-1.17)	0.293	0.92(0.78-1.07)	0.267	1.05(0.996-1.11)	0.069	0.98(0.90-1.06)	0.608
	Cornell voltage	1.08(0.96-1.22)	0.185	0.98(0.84-1.15)	0.815	<b>1.12(1.05-1.20)</b>	<b>0.001</b>	0.97(0.89-1.07)	0.543
	Model 2	Peak QRS-T angle	<b>1.21(1.10-1.33)</b>	<b>&lt;0.0001</b>	0.89(0.76-1.04)	0.130	<b>0.93(0.87-0.98)</b>	<b>0.010</b>	1.02(0.93-1.12)
Area QRS-T angle		<b>1.26(1.13-1.41)</b>	<b>&lt;0.0001</b>	<b>0.82(0.69-0.96)</b>	<b>0.017</b>	<b>0.92(0.87-0.97)</b>	<b>0.004</b>	1.02(0.92-1.13)	0.656
Peak SVG elevation		<b>1.16(1.04-1.29)</b>	<b>0.007</b>	0.96(0.80-1.15)	0.649	<b>0.92(0.86-0.98)</b>	<b>0.006</b>	1.07(0.95-1.21)	0.281
Area SVG elevation		<b>1.11(1.005-1.24)</b>	<b>0.041</b>	0.98(0.82-1.17)	0.849	<b>0.93(0.88-0.99)</b>	<b>0.031</b>	1.05(0.93-1.18)	0.418
Peak SVG azimuth		<b>1.11(1.01-1.22)</b>	<b>0.033</b>	1.04(0.88-1.23)	0.651	<b>0.95(0.90-0.999)</b>	<b>0.044</b>	1.01(0.91-1.12)	0.887
Area SVG azimuth		1.04(0.93-1.16)	0.458	1.10(0.89-1.81)	0.360	0.96(0.91-1.02)	0.171	0.97(0.87-1.07)	0.549
Peak SVG magnitude		0.91(0.79-1.04)	0.180	1.20(0.99-1.44)	0.058	1.04(0.97-1.12)	0.273	0.94(0.84-1.05)	0.248
Area SVG magnitude		0.99(0.83-1.08)	0.425	1.14(0.96-1.37)	0.144	1.04(0.97-1.12)	0.273	0.93(0.83-1.03)	0.179
SAI QRST		<b>1.10(1.02-1.19)</b>	<b>0.011</b>	0.99(0.87-1.12)	0.831	0.95(0.90-1.01)	0.083	0.97(0.89-1.05)	0.447
Heart rate.		1.03(0.92-1.15)	0.589	1.05(0.88-1.25)	0.583	<b>1.11(1.04-1.18)</b>	<b>0.001</b>	0.97(0.88-1.08)	0.590
Bazett's QTc		<b>1.13(1.03-1.24)</b>	<b>0.009</b>	1.02(0.89-1.16)	0.792	1.02(0.97-1.09)	0.413	0.96(0.88-1.06)	0.418
QRS duration		<b>1.20(1.10-1.30)</b>	<b>&lt;0.0001</b>	0.96(0.83-1.10)	0.530	<b>0.92(0.87-0.97)</b>	<b>0.002</b>	0.98(0.89-1.08)	0.713
Cornell voltage		1.05(0.96-1.15)	0.257	1.09(0.96-1.24)	0.204	0.97(0.92-1.02)	0.187	1.00(0.92-1.08)	0.937

RSHR=relative sub-hazard ratio

**Supplemental Table 2B. Competing risks of sudden cardiac death and non-sudden cardiovascular death for white and black participants**

Predictor, per 1 SD	Sudden cardiac death				Non-sudden cardiac death				
	White (n=10,669;309 SCDs)		Black (n=3,739; 213 SCDs)		White (n=10,669;309 SCDs)		Black (n=3,739; 213 SCDs)		
	SHR(95%CI)	P-value	SHR(95%CI)	P-value	SHR(95%CI)	P-value	SHR(95%CI)	P-value	
Model 1	Peak QRS-T angle	<b>1.27(1.15-1.40)</b>	<b>&lt;0.0001</b>	1.09(0.96-1.24)	0.167	<b>1.10(1.04-1.16)</b>	<b>0.002</b>	<b>1.15(1.07-1.23)</b>	<b>&lt;0.0001</b>
	Area QRS-T angle	<b>1.26(1.12-1.42)</b>	<b>&lt;0.0001</b>	1.00(0.87-1.15)	0.975	<b>1.14(1.07-1.21)</b>	<b>&lt;0.0001</b>	<b>1.19(1.09-1.29)</b>	<b>&lt;0.0001</b>
	Peak SVG elevation	1.10(0.97-1.26)	0.130	1.09(0.93-1.29)	0.293	0.99(0.93-1.05)	0.783	0.96(0.87-1.06)	0.403
	Area SVG elevation	<b>1.15(1.04-1.27)</b>	<b>0.008</b>	1.09(0.94-1.27)	0.257	0.98(0.93-1.04)	0.559	1.00(0.92-1.09)	0.959
	Peak SVG azimuth	1.08(0.98-1.19)	0.116	1.12(0.98-1.28)	0.095	1.04(0.99-1.10)	0.137	1.01(0.93-1.11)	0.746
	Area SVG azimuth	0.97(0.87-1.08)	0.594	1.04(0.89-1.22)	0.625	<b>1.08(1.02-1.14)</b>	<b>0.013</b>	1.05(0.97-1.15)	0.220
	Peak SVG magnitude	0.92(0.81-1.05)	0.229	0.97(0.85-1.11)	0.636	0.97(0.91-1.04)	0.362	1.03(0.96-1.12)	0.344
	Area SVG magnitude	1.01(0.89-1.14)	0.933	0.98(0.86-1.13)	0.823	0.99(0.93-1.07)	0.885	1.06(0.98-1.15)	0.122
	SAI QRST	<b>1.16(1.03-1.31)</b>	<b>0.012</b>	1.00(0.88-1.15)	0.953	1.04(0.96-1.12)	0.325	<b>1.11(1.03-1.20)</b>	<b>0.010</b>
	Heart rate.	1.05(0.93-1.19)	0.450	1.04(0.91-1.19)	0.526	<b>1.14(1.08-1.21)</b>	<b>&lt;0.0001</b>	<b>1.19(1.10-1.28)</b>	<b>&lt;0.0001</b>
	Bazett's QTc	1.11(0.99-1.25)	0.069	1.10(0.99-1.22)	0.066	<b>1.06(1.00-1.12)</b>	<b>0.037</b>	1.05(0.98-1.12)	0.180
	QRS duration	1.05(0.94-1.17)	0.420	1.01(0.88-1.16)	0.880	1.03(0.97-1.09)	0.371	1.07(0.99-1.16)	0.085
	Cornell voltage	1.05(0.93-1.19)	0.460	1.09(0.97-1.23)	0.140	<b>1.12(1.04-1.20)</b>	<b>0.002</b>	<b>1.11(1.03-1.06)</b>	<b>0.006</b>
	Model 2	Peak QRS-T angle	<b>1.21(1.09-1.33)</b>	<b>&lt;0.0001</b>	1.07(0.93-1.24)	0.340	<b>0.93(0.87-0.98)</b>	<b>0.014</b>	0.94(0.86-1.02)
Area QRS-T angle		<b>1.26(1.13-1.41)</b>	<b>&lt;0.0001</b>	1.04(0.89-1.20)	0.644	<b>0.92(0.87-0.98)</b>	<b>0.008</b>	0.92(0.84-1.02)	0.115
Peak SVG elevation		<b>1.17(1.05-1.30)</b>	<b>0.005</b>	1.12(0.95-1.32)	0.195	<b>0.91(0.85-0.97)</b>	<b>0.003</b>	1.01(0.91-1.13)	0.793
Area SVG elevation		<b>1.13(1.02-1.26)</b>	<b>0.020</b>	1.10(0.94-1.30)	0.243	<b>0.93(0.87-0.99)</b>	<b>0.032</b>	1.01(0.91-1.12)	0.812
Peak SVG azimuth		<b>1.10(1.004-1.22)</b>	<b>0.042</b>	1.16(0.99-1.35)	0.068	0.95(0.90-1.00)	0.061	0.94(0.85-1.04)	0.254
Area SVG azimuth		1.04(0.93-1.16)	0.453	1.14(0.95-1.38)	0.169	0.97(0.92-1.02)	0.229	<b>0.91(0.82-0.998)</b>	<b>0.046</b>
Peak SVG magnitude		0.95(0.83-1.09)	0.455	1.04(0.91-1.19)	0.541	1.04(0.97-1.23)	0.262	0.96(0.88-1.04)	0.336
Area SVG magnitude		0.98(0.86-1.12)	0.791	1.05(0.91-1.21)	0.530	1.04(0.97-1.12)	0.245	0.95(0.87-1.03)	0.222
SAI QRST		<b>1.11(1.03-1.20)</b>	<b>0.007</b>	1.09(0.97-1.23)	0.148	0.95(0.90-1.01)	0.079	<b>0.92(0.86-0.99)</b>	<b>0.018</b>
Heart rate		1.03(0.92-1.16)	0.630	1.12(0.97-1.30)	0.114	<b>1.12(1.06-1.19)</b>	<b>&lt;0.0001</b>	1.06(0.98-1.16)	0.158
Bazett's QTc		<b>1.15(1.05-1.27)</b>	<b>0.003</b>	<b>1.15(1.03-1.28)</b>	<b>0.011</b>	1.02(0.97-1.08)	0.439	1.02(0.93-1.08)	0.953

QRS duration	<b>1.19(1.09-1.30)</b>	<b>&lt;0.0001</b>	<b>1.16(1.02-1.31)</b>	<b>0.019</b>	<b>0.91(0.86-0.96)</b>	<b>0.001</b>	0.92(0.84-1.002)	0.056
Cornell voltage	1.07(0.97-1.17)	0.159	<b>1.14(1.03-1.27)</b>	<b>0.015</b>	0.97(0.92-1.02)	0.182	0.96(0.89-1.03)	0.224

**Supplemental Table 3. Relative risk of SCD associated with SVG magnitude and QRS-T angle in race-hypertension categories**

	Race-Hypertension category	Peak QRS-T angle, per 1SD		Area QRS-T angle, per 1SD		Peak SVG magnitude, per 1SD		Area SVG magnitude, per 1SD	
		RHR(95%CI)	P-value	RHR(95%CI)	P-value	RHR(95%CI)	P-value	RHR(95%CI)	P-value
Cox Model 1	White HTN-free (n=7,784)	Reference (1)		Reference (1)		Reference (1)		Reference (1)	
	White with HTN (n=2,885)	0.94(0.79-1.12)	0.507	0.93(0.77-1.13)#	0.458	1.26(0.98-1.61)#	0.066	1.28(0.99-1.64)#	0.055
	Black with HTN (n=2,077)	<b>0.82(0.70-0.97)</b>	<b>0.021</b>	<b>0.71(0.59-0.86)</b>	<b>&lt;0.0001</b>	<b>1.32(1.05-1.65)</b>	<b>0.016</b>	1.25(0.999-1.56)	0.051
	Black HTN-free (n=1,662)	0.87(0.66-1.14)	0.304	1.04(0.71-1.53)	0.681	<b>1.44(1.04-2.01)</b>	<b>0.030</b>	1.35(0.98-1.85)	0.070
Cox Model 2	White HTN-free (n=7,784)	Reference (1)		Reference (1)		Reference (1)		Reference (1)	
	White with HTN (n=2,885)	0.88(0.74-1.06)	0.170	0.92(0.76-1.10)	0.359	1.18(0.91-1.54)	0.203	1.17(0.91-1.51)	0.218
	Black with HTN (n=2,077)	<b>0.82(0.69-0.98)</b>	<b>0.029</b>	<b>0.76(0.62-0.91)</b>	<b>0.004</b>	<b>1.30(1.03-1.63)</b>	<b>0.026</b>	1.25(0.999-1.56)	0.051
	Black HTN-free (n=1,662)	0.83(0.62-1.12)	0.229	0.93(0.68-1.26)	0.631	<b>1.49(1.08-2.05)</b>	<b>0.014</b>	<b>1.41(1.03-1.92)</b>	<b>0.031</b>
		RSHR(95%CI)	P-value	RSHR(95%CI)	P-value	RSHR(95%CI)	P-value	RSHR(95%CI)	P-value
Competing SCD model 1	White HTN-free (n=7,784)	Reference (1)		Reference (1)		Reference (1)		Reference (1)	
	White with HTN (n=2,885)	0.93(0.78-1.09)	0.368	0.93(0.77-1.12)	0.448	1.26(0.99-1.60)	0.063	<b>1.27(1.01-1.61)</b>	<b>0.043</b>
	Black with HTN (n=2,077)	<b>0.79(0.67-0.93)</b>	<b>0.005</b>	<b>0.71(0.59-0.86)</b>	<b>&lt;0.0001</b>	1.19(0.96-1.48)	0.120	1.12(0.90-1.38)	0.314
	Black HTN-free (n=1,662)	0.93(0.71-1.23)	0.611	1.04(0.74-1.44)	0.834	<b>1.42(1.07-1.89)</b>	<b>0.017</b>	<b>1.32(1.00-1.76)</b>	<b>0.050</b>
Competing SCD model 2	White HTN-free (n=7,784)	Reference (1)		Reference (1)		Reference (1)		Reference (1)	
	White with HTN (n=2,885)	0.87(0.72-1.04)	0.134	0.90(0.74-1.10)	0.320	1.15(0.87-1.51)	0.326	1.16(0.90-1.51)	0.255
	Black with HTN (n=2,077)	<b>0.80(0.67-0.96)</b>	<b>0.019</b>	<b>0.72(0.59-0.89)</b>	<b>0.002</b>	1.22(0.97-1.53)	0.090	1.18(0.94-1.48)	0.155
	Black HTN-free (n=1,662)	0.87(0.64-1.17)	0.348	0.97(0.71-1.33)	0.850	<b>1.50(1.07-2.09)</b>	<b>0.018</b>	<b>1.44(1.05-1.96)</b>	<b>0.023</b>
Competing nonSCD model 1	White HTN-free (n=7,784)	Reference (1)		Reference (1)		Reference (1)		Reference (1)	
	White with HTN (n=2,885)	0.90(0.81-0.99)	0.032	0.90(0.82-1.01)	0.066	0.97(0.85-1.10)	0.599	0.98(0.86-1.11)	0.730
	Black with HTN (n=2,077)	0.94(0.85-1.04)	0.259	0.94(0.84-1.05)	0.303	1.10(0.98-1.25)	0.112	1.09(0.96-1.22)	0.172
	Black HTN-free (n=1,662)	0.98(0.65-1.13)	0.764	0.93(0.79-1.11)	0.435	0.97(0.80-1.16)	0.708	0.99(0.83-1.18)	0.890
Competing nonSCD model 2	White HTN-free (n=7,784)	Reference (1)		Reference (1)		Reference (1)		Reference (1)	
	White with HTN (n=2,885)	0.93(0.83-1.04)	0.219	0.93(0.83-1.03)	0.164	0.95(0.83-1.10)	0.493	0.88(0.76-1.00)	0.056
	Black with HTN (n=2,077)	0.96(0.86-1.09)	0.558	0.99(0.87-1.12)	0.814	0.92(0.81-1.05)	0.235	0.88(0.76-1.00)	0.053
	Black HTN-free (n=1,662)	1.02(0.87-1.20)	0.797	0.97(0.80-1.16)	0.724	0.88(0.74-1.05)	0.146	<b>0.83(0.70-0.99)</b>	<b>0.042</b>






### Supplemental Figure Legends:


**Supplemental Figure 1:** Estimated adjusted marginal (least-squares) means and 95% Confidence Intervals of (A) area QRS-T angle, (B) peak QRS-T angle, (C) area SVG azimuth, (D) peak SVG azimuth, (E) area SVG elevation, (F) peak SVG elevation, (G) QRS duration, (H) QTc interval for white and black participants. Model 1 was adjusted for age, sex, and study center. Model 2 was additionally adjusted for HF, CHD, stroke, diabetes, hypertension, current smoking and alcohol intake, work, sport, and leisure physical activity levels, levels of total cholesterol, high density lipoprotein, and triglycerides, BMI, use of antihypertensive and antiarrhythmic medications, serum concentrations of sodium, potassium, calcium, magnesium, phosphorus, and uric acid, total protein and albumin, blood urea nitrogen, and CKD stage classified by eGFR<sub>CKD-EPI</sub>, heart rate, QRS duration, Bazett-corrected QT interval, Cornell voltage, education level, occupation category, income, and health insurance.

**Supplemental Figure 2:** Adjusted (model 1) risk of SCD associated with an area (A) and peak (B) SVG magnitude in black and white participants. Restricted cubic spline with 95% CI shows change in hazard ratio (Y-axis) in response to SVG magnitude change (X-axis). 50th percentile of SVG magnitude is selected as reference. Knots of area SVG magnitude in black participants are at 1.2 – 1.7 – 2.1 – 2.9 mV, and in white participants are at 1.0 – 1.4 – 1.8 – 2.4 mV. Knots of peak SVG magnitude in black participants are at 1.1 – 1.6 – 2.0 – 2.6 mV, and in white participants are at 0.9 – 1.4 – 1.7 – 2.2 mV.


Supplemental Figure 1 A:




Supplemental Figure 1 B:




Supplemental Figure 1 C:




Supplemental Figure 1 D:




Supplemental Figure 1 E:



Supplemental Figure 1 F:




Supplemental Figure 1 G:







Supplemental Figure 1 H:



Supplemental Figure 1 I:



Supplemental Figure 2A:



Supplemental Figure 2B:

